jetrea 0.5mg0.2ml concentrate for solution for injection vials
alcon eye care ltd - ocriplasmin - solution for injection - 2.5mg/1ml
vabysmo
roche pharmaceuticals (israel) ltd - faricimab - solution for injection - faricimab 120 mg/ml - faricimab - vabysmo is a vascular endothelial growth factor (vegf) and angiopoietin 2 (ang-2) inhibitor indicated for the treatment of patients with:• neovascular (wet) age-related macular degeneration (namd) • diabetic macular edema (dme)
susvimo- ranibizumab injection, solution
genentech, inc. - ranibizumab (unii: zl1r02vt79) (ranibizumab - unii:zl1r02vt79) - susvimo (ranibizumab injection) is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (amd) who have previously responded to at least two intravitreal injections of a vascular endothelial growth factor (vegf) inhibitor medication. susvimo (ranibizumab injection) is contraindicated in patients with ocular or periocular infections. susvimo (ranibizumab injection) is contraindicated in patients with active intraocular inflammation. susvimo (ranibizumab injection) is contraindicated in patients with known hypersensitivity to ranibizumab products or any of the excipients in susvimo (ranibizumab injection). risk summary there are no adequate and well-controlled studies of susvimo (ranibizumab injection) administration in pregnant women. administration of ranibizumab to pregnant monkeys throughout the period of organogenesis resulted in a low incidence of skeletal abnormalities at intravitreal doses up to 41 times the human exposure (based on serum levels following the re
lucentis 10 mg/ml solution for injection (intravitreal)
novartis healthcare philippines, inc. - ranibizumab - solution for injection (intravitreal) - 10 mg/ml
lucentis 10 mg/ml solution for injection (intravitreal)
sandoz philippines corporation - ranibizumab - solution for injection (intravitreal) - 10 mg/ml
lucentis 10mg / ml solution for injection (intravitreal)
novartis healthcare philippines, inc. - ranizumab - solution for injection (intravitreal) - 10mg / ml
iluvien 190 µg i.vitreal implant (applic.) i.vitr. applic.
alimera sciences europe ltd. - fluocinolone acetonide 0,19 mg - intravitreal implant in applicator - 190 µg - fluocinolone acetonide 0.19 mg - fluocinolone acetonide
iluvien
megapharm ltd - fluocinolone acetonide - intravitreal injection - fluocinolone acetonide 190 mcg - fluocinolone acetonide - iluvien is indication for the treatment of vision impairment associated with chronic diabetic macular edema (dme), considered insufficiently responsive to available therapies
iluvien
alimera sciences limited - fluocinolone acetonide - 190 microgram - fluocinolone acetonide
ozurdex 700 mcg implante intravítreo